Intravenous Bolus Topotecan in Patients with Myelodysplastic Syndrome

Karen Seiter Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New YorkCorrespondence[email protected]

Delong Liu Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New York

Eric J. Feldman Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New York

Ahmad D. Siddiqui Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New York

Albert Hoang Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New York

Paul Baskind Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New York

Ram Kancherla Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New York

Tauseef Ahmed Zalmen A. Arlin Cancer Institute, Department of Medicine New York Medical College Valhalla, New York

show all

Abstract

We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m²/d, 2.0 mg/m²/d or 2.5 mg/m²/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Intravenous Bolus Topotecan in Patients with Myelodysplastic Syndrome

Information for

Open access

Opportunities

Help and information

Intravenous Bolus Topotecan in Patients with Myelodysplastic Syndrome

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature